tbuckley/cabot-search huggingface dataset:
NSABP FR-2: Phase II study of durvalumab following neoadjuvant chemotherapy (NAC) in stage II-IV rectal cancer.
Authors: Thomas J. George, Greg Yothers, James J. Lee, Samuel A. Jacobs, Melvin Deutsch, Carmen Joseph Allegra, Norman Wolmark
Journal: Journal of Clinical Oncology (2018)

TPS3624 Background: Locally-advanced rectal cancer (LARC) remains a clinical challenge with few improvements noted over the past few decades. Although immunotherapy has no current clinical role in microsatellite stable (MSS) colorectal cancer, preclinical models suggest that radiotherapy (RT) can induce neoantigen presentation, modulate the microenvironment, and improve the likelihood of immunogenic activation with checkpoint inhibitor use. This prospective phase II study will test that hypothesis in addition to confirming safety of this approach using a “window-of-opportunity” study design with the anti-PDL1 agent durvalumab (MEDI4736). Methods: This multi-center phase II trial is currently enrolling patients (pts) with rectal cancer who are undergoing standard NCCN guideline-compliant NAC and RT. Eligibility includes pts with MSS stage II-IV rectal cancer with adequate organ function and pre-treatment diagnostic tumor available for profiling who are undergoing NAC with intentions to proceed to surgical resection. Stage IV disease must be limited such that the primary pelvic tumor requires definitive management. Standard ineligibility criteria include active infections, systemic steroid use, or other conditions making immunotherapy use unsafe. Treatment includes durvalumab (750mg IV infusion once every 2 wks) for 4 total doses beginning within 3-7 days after NAC completion. Surgery must be within 8-12 wks of the final RT dose. Primary endpoint is a demonstrated improvement in Neoadjuvant Rectal Cancer (NAR) score compared to historical controls representing a 20% relative risk reduction in DFS HR and 3-4% absolute OS improvement. Secondary endpoints include comparisons of OS, DFS, toxicity, pCR, cCR, therapy completion, negative surgical margins, sphincter preservation, off-target “abscopal” effects for the subset of stage IV pts, and exploratory assessments of tumor infiltrating lymphocytes, circulating immunologic profiles, and molecular predictors of response. A safety run-in portion of the study will precede full enrollment. Enrollment continues to 47 total pts to achieve 41 surgically evaluable pts. Support: AstraZeneca-Medimmune, NSABP Foundation Clinical trial information: NCT03102047.
Keeping up with Cancer
Journal: CA A Cancer Journal for Clinicians (1953)

Radium Therapy inCervical Cancer about tumors or at certain vulnerable points in normal tissues can be deter mined, radium sources will be better placed to destroy cancer effectively and to avoid overdosage and destruction of normal tissues leading to recurrence and severe complications.With the help of the radiophysicists in improv ing distribution of the needles and per haps with improvement in roentgen rayâ€"radiation technique, even better results are awaited in the future.
Abstract 810: Differential use of lactate for mitochondria respiration by NSCLC cells
Authors: Pamela Swain, Natalia Romero, Yoonseok Kam, Brian P. Dranka
Journal: Cancer Research (2019)

Abstract Metabolic liabilities in cancer cells provide the opportunity for novel therapeutic approaches. This is especially true as the dogma that all cancer cells are glycolytic is being challenged. Phenotypic screening of cancer cell lines can demonstrate what these liabilities are and suggest approaches for drugs that target these vulnerabilities. As an example, non-small cell lung cancer (NSCLC) is typically driven by oncogenic mutations in either KRAS or EGFR. However, the impact of these mutations on cellular metabolic phenotype is not well-studied. In this study, we observed that the two KRAS-mutated NSCLC cell lines (A549 and H460) primarily relied on glycolysis for ATP production while EGFR-mutated cell lines (H1975 and PC9) were more reliant on mitochondrial respiration to meet energy demands. There is emerging evidence to suggest that lactate is a major fuel for cancer cell energy metabolism especially in the glucose-limited tumor microenvironment. Thus, we next compared the use of lactate with other carbon sources for ATP production in NSCLC cells. We found there was differential usage of lactate for mitochondrial respiration between KRAS and EGFR-mutated NSCLC cells. EGFR-mutated NSCLC cells used lactate and increased mitochondrial respiration when lactate was acutely administrated regardless of glucose availability. In contrast, the use of lactate for the mitochondrial respiration by KRAS-mutated cells was limited. In A549 cells, no significant change in mitochondrial respiration rate was observed at all by acute injection of lactate. Together, these results imply that NSCLC variants have adopted different metabolic phenotypes depending on the oncogenic background and more oxidative phenotype may be correlated to higher lactate use for TCA cycle in production of ATP. Citation Format: Pamela Swain, Natalia Romero, Yoonseok Kam, Brian P. Dranka. Differential use of lactate for mitochondria respiration by NSCLC cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 810.
Of lungs and leukocytes
Authors: D. E. Hammerschmidt
Journal: JAMA (1980)

The publication more than three centuries ago of Harvey's<i>De Motu Cardis</i>laid the theoretical foundation for blood transfusion. Early attempts followed soon thereafter and often met with disastrous outcome; even the reports of early "successes" contain vivid description of acute intravascular hemolysis, complete with back pain, fever, confusion, and hemoglobinuria.<sup>1</sup>In this century, the major and minor erythrocyte antigens have been recognized and practical techniques for anticoagulation, storage, and compatibility testing of blood have been devised. Once a desperate gamble, blood transfusion has become a safe and routine procedure. But the goal of complete safety remains elusive. Sensitization to minor RBC antigens may occur in consequence of pregnancy or prior transfusion, occasionally escaping detection in cross matching and resulting in hemolytic transfusion reactions. Our methods for excluding carriers of the hepatitis viruses (A, B, and non-A, non-B) from blood donation are primitive.<sup>2</sup>A third problem of particular
THE OLDEST PRESCRIPTION IN AMERICA
Journal: JAMA (2011)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Rubinstein-Taybi syndrome
Authors: M. F. Lowry
Journal: JAMA (1968)

<h3>To the Editor:—</h3> The answer to the query concerning the appropriate anticoagulant for the Westergren method for determining the erythrocyte sedimentation rate (<b>205</b>:653, 1968) does not emphasize the considerable influence that the anticoagulant may have on the results. Gambino et al (<i>Amer J Clin Path</i><b>43</b>: 173, 1965) and Dawson (<i>Brit Med J</i><b>1</b>:1697, 1960) have shown that blood collected in edetic acid (EDTA) yields unreliable and irreproducible erythrocyte sedimentation rates in the Westergren tube, unless a dilution of the whole blood is made in the test procedure. My own experience confirms the work of these authors. In view of the widespread adoption of the EDTA anticoagulant for hematologic studies, it would seem essential to use a diluted blood aliquot in the Westergren technique if this test is to have any value at all, in terms of accurate reflection of clinical status and of standardization.
THE ROLE OF THE TOXINS IN INFLAMMATORY PROCESSES.
Journal: JAMA (1902)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Diagnosis of Smallpox by Immunofluorescence
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Book Review Communicable Disease Control: A volume for the health officer and public health nurse . By Gaylord W. Anderson, M.D., and Margaret G. Arnstein, R.N., M.A., M.P.H. 8°, cloth, 434 pp., with 13 tables. New York: The Macmillan Company, 1941. $4.25.
Journal: New England Journal of Medicine (1942)
Symposium on Breast Disease in Gynecological and Medical Primary Care Practice
Journal: JNCI Journal of the National Cancer Institute (1977)

Symposium on Breast Disease in Gynecological and Medical Primary Care Practice Get access JNCI: Journal of the National Cancer Institute, Volume 58, Issue 2, February 1977, Page 467, https://doi.org/10.1093/jnci/58.2.467 Published: 01 February 1977
Correction: Severe peritonitis after successful endoscopic ultrasound-guided gallbladder drainage for acute gangrenous cholecystitis
Authors: Toji Murabayashi, Yoshihide Kanno, Kei Ito, Shinsuke Koshita, Takahisa Ogawa, Masaya Oikawa, Yutaka Noda
Journal: Endoscopy (2018)

Correction to: Severe peritonitis after successful endoscopic ultrasound-guided gallbladder drainage for acute gangrenous cholecystitisEndoscopy 2018; 50(06): 642-643DOI: 10.1055/a-0591-2630
Immunologic Responses to Inhaled Cotton Dust
Authors: John E. Salvaggio, Carol E. O'Neil, Brian T. Butcher
Journal: Environmental Health Perspectives (1986)

Byssinosis, a respiratory disease of workers on cotton, flax, and soft hemp, is classically characterized as shortness of breath, cough, and chest tightness on Mondays or the first day of return to work after a time off. Exposure to these vegetable dusts can also result in other respiratory diseases, and the term cotton dust-induced respiratory disease (CDIRD) is introduced. Although clinically characterized for more than a century, the underlying pathogenesis of CDIRD remains obscure. An allergic pathogenesis has been proposed. This article reviews previous and current research findings supporting this mechanism and raises the possibility that, in some individuals, CDIRD may be due to pre-existing or occupationally induced mold allergy.
Book Review History of Pharmacy: A guide and a survey . By Edward Kremers, Ph.G., Ph.M., Ph.D., Sc.D.; and George Urdang, Ph.G., D.Sc. Nat. 8°, cloth, 466 pp., with 30 illustrations. Philadelphia: J. B. Lippincott Company, 1940. $4.50.
Journal: New England Journal of Medicine (1941)
Metabolic Alkalinization in Porphyria Cutanea Tarda
Journal: JAMA (1969)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Antiviral Therapy and Hepatitis B Virus–Related Hepatocellular Carcinoma Recurrence
Authors: Ching-Sheng Hsu
Journal: JAMA (2013)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Association News
Journal: JAMA (1935)

<h3>MEDICAL BROADCASTS</h3> Columbia Broadcasting System The American Medical Association broadcasts on a western network of the Columbia Broadcasting System each Thursday afternoon on the Educational Forum from 4: 30 to 4:45, central standard time. The next three broadcasts will be delivered by Dr. W. W. Bauer. The titles will be as follows: March 21. Rickets. March 28. This Is No April Fool. April 4. Negro Health Week. <h3>National Broadcasting Company</h3> The American Medical Association broadcasts under the title "Your Health" on a Blue network of the National Broadcasting Company each Tuesday afternoon from 4 to 4:15, central standard time. The next three broadcasts will be as follows: March 19. White Collar Hazards, W. W. Bauer, M.D. March 26. Tonics and Sedatives, Morris Fishbein, M.D. April 2. Sickness Insurance, R. G. Leland, M.D.
Vorlesungen über allgemeine Konstitutions- und Vererbungslehre für Studierende und Aerzte.
Journal: JAMA (1924)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Withholding of life-sustaining treatment from the terminal ill, incompetent patient: who decides? Part I
Authors: D. G. Suber
Journal: JAMA (1982)

As a result of the prodigious technological advances of modern medicine, physicians are increasingly confronted with the question of when, and under what circumstances, life-sustaining care should be withdrawn from terminally ill patients. In the wake of recent court decisions recognizing patients' rights to refuse medical treatment, new complexities have been introduced into the process of deciding whether so-called "extraordinary measures" should be used to prolong life. Chief among these is the problem of determining who, in addition to the physician, should be involved in making such decisions. As the dilemma often arises in the context of treatment of patients who are incapacitated or mentally deficient and, thus, legally incompetent to render informed consent, the question of "who should decide" has emerged as the central issue facing the physician and the courts. Also of primary concern to physicians is the associated question of what legal consequences might follow from the
Erratum
Journal: BMJ (1897)

vary.As to rooms in the students' quarters, there is no difficulty; board and lodging can be got en pension for 6 francs per diem and up- wards, though it might be more advisable to take a room in one of the numerous hotels, and feed at a restaurant, which is cheaper.Should your correspondent wish for further information, I shall be pleased to give him what information I can if he will write direct to the above address.Dn.HARRY GREY (San Remo
Pentazocine Abuse
Authors: Thomas E. Kirts
Journal: JAMA (1973)

<h3>To the Editor.—</h3> I am pleased to read reports of pentazocine abuse by Halliday (223:801, 1973) and Finkelstein (224:249, 1973). While reported cases of pentazocine abuse are rare in the literature, there is some indication that it is becoming common at this time. <h3>Report of a Case.—</h3> A 25-year-old male college student was married two months prior to his first seeing me. He was given his first injection by his mother who had access to medication because of a chronic disease. The patient had severe low back pain due to doing heavy construction work, and his mother gave him an injection to ease the pain. She continued to give him injections occasionally for some time due to his pain, and eventually the patient began taking the pentazocine on his own. He began to use his mother's supply and also obtained the pentazocine by calling different physicians who were friends of
Abstract LB-262: Targeting of the PI3K/AKT pathway overcomes enzalutamide resistance by inhibiting the induction of glucocorticoid receptor
Authors: Remi M. Adelaiye-Ogala, Kathleen Kelly, David VanderWeele
Journal: Cancer Research (2019)

Abstract Background: An evolving concept that contributes to the understanding of resistance to androgen deprivation therapy and/or androgen receptor (AR) antagonist in prostate cancer is the ability of the cells to bypass AR blockade and turn on compensatory hormone signaling for survival. Recent preclinical and clinical studies demonstrate that induction of GR expression confers resistance to AR-targeted therapy. Hence therapeutic strategies to overcome GR-mediated resistance are warranted. Experimental Design: Prostate cancer cell-lines and patient derived xenograft (PDX) models were exposed to the pan-AKT inhibitor ipatasertib or other PI3K/AKT- pathway inhibitors with or without AR blockade. AR and GR array determined differentially expressed AR/GR target genes. Protein expression levels were measured. Cell viability and tumor growth was determined in response to treatment. Results: AKT inhibitor as monotherapy significantly decreases cell viability across multiple prostate cancer models. The cytotoxic effect is enhanced by AR inhibition and is most pronounced in models that induce compensatory GR expression. The pan-AKT inhibitor ipatasertib as well as other inhibitors of the PI3K/AKT pathway decreased GR activity through AR-dependent and AR-independent mechanisms. Importantly, AKT inhibition, with and without AR blockade, demonstrated significant anti-tumor activity in several in vivo prostate cancer models with no noticeable toxicity. Conclusion: Inhibition of the PI3K/AKT pathway blocks GR activity and overcomes GR-mediated resistance to AR-targeted therapy. This therapeutic approach has immediate clinical relevance as ipatasertib is currently in advanced clinical development and provides a supportive tool for how to manage patients with acquired resistant to AR-targeted therapy. Citation Format: Remi M. Adelaiye-Ogala, Kathleen Kelly, David VanderWeele. Targeting of the PI3K/AKT pathway overcomes enzalutamide resistance by inhibiting the induction of glucocorticoid receptor [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr LB-262.